Literature DB >> 22033505

Production of N-acetylgalactosaminyl-transferase 2 (GalNAc-T2) fused with secretory signal Igκ in insect cells.

Milada Horynová1, Kazuo Takahashi, Stacy Hall, Matthew B Renfrow, Jan Novak, Milan Raška.   

Abstract

The human UDP-N-acetyl-α-d-galactosamine:polypeptide N-acetylgalactosaminyl-transferase 2 (GalNAc-T2) is one of the key enzymes that initiate synthesis of hinge-region O-linked glycans of human immunoglobulin A1 (IgA1). We designed secreted soluble form of human GalNAc-T2 as a fusion protein containing mouse immunoglobulin light chain kappa secretory signal and expressed it using baculovirus and mammalian expression vectors. The recombinant protein was secreted by insect cells Sf9 and human HEK 293T cells in the culture medium. The protein was purified from the media using affinity Ni-NTA chromatography followed by stabilization of purified protein in 50mM Tris-HCl buffer at pH 7.4. Although the purity of recombinant GalNAc-T2 was comparable in both expression systems, the yield was higher in Sf9 insect expression system (2.5mg of GalNAc-T2 protein per 1L culture medium). The purified soluble recombinant GalNAc-T2 had an estimated molecular mass of 65.8kDa and its amino-acid sequence was confirmed by mass-spectrometric analysis. The enzymatic activity of Sf9-produced recombinant GalNAc-T2 was determined by the quantification of enzyme-mediated attachment of GalNAc to synthetic IgA1 hinge-region peptide as the acceptor and UDP-GalNAc as the donor. In conclusion, murine immunoglobulin kappa secretory signal was used for production of secreted enzymatically active GalNAc-T2 in insect baculovirus expression system.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22033505      PMCID: PMC3637031          DOI: 10.1016/j.pep.2011.10.006

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  26 in total

1.  Regulation of histone H2A and H2B deubiquitination and Xenopus development by USP12 and USP46.

Authors:  Heui-Yun Joo; Amada Jones; Chunying Yang; Ling Zhai; Archer D Smith; Zhuo Zhang; Mahesh B Chandrasekharan; Zu-wen Sun; Matthew B Renfrow; Yanming Wang; Chenbei Chang; Hengbin Wang
Journal:  J Biol Chem       Date:  2010-12-23       Impact factor: 5.157

2.  Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: a comparative binding study.

Authors:  Michelle M Gomes; Hitoshi Suzuki; Monica T Brooks; Milan Tomana; Zina Moldoveanu; Jiri Mestecky; Bruce A Julian; Jan Novak; Andrew B Herr
Journal:  Biochemistry       Date:  2010-07-13       Impact factor: 3.162

3.  Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.

Authors:  Hitoshi Suzuki; Run Fan; Zhixin Zhang; Rhubell Brown; Stacy Hall; Bruce A Julian; W Winn Chatham; Yusuke Suzuki; Robert J Wyatt; Zina Moldoveanu; Jeannette Y Lee; James Robinson; Milan Tomana; Yasuhiko Tomino; Jiri Mestecky; Jan Novak
Journal:  J Clin Invest       Date:  2009-05-26       Impact factor: 14.808

4.  Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteins.

Authors:  Jennifer S Moore; Rose Kulhavy; Milan Tomana; Zina Moldoveanu; Hitoshi Suzuki; Rhubell Brown; Stacy Hall; Mogens Kilian; Knud Poulsen; Jiri Mestecky; Bruce A Julian; Jan Novak
Journal:  Mol Immunol       Date:  2007-02-02       Impact factor: 4.407

5.  The lectin domains of polypeptide GalNAc-transferases exhibit carbohydrate-binding specificity for GalNAc: lectin binding to GalNAc-glycopeptide substrates is required for high density GalNAc-O-glycosylation.

Authors:  Hans H Wandall; Fernando Irazoqui; Mads Agervig Tarp; Eric P Bennett; Ulla Mandel; Hideyuki Takeuchi; Kentaro Kato; Tatsuro Irimura; Ganesh Suryanarayanan; Michael A Hollingsworth; Henrik Clausen
Journal:  Glycobiology       Date:  2007-01-10       Impact factor: 4.313

6.  Clustered O-glycans of IgA1: defining macro- and microheterogeneity by use of electron capture/transfer dissociation.

Authors:  Kazuo Takahashi; Stephanie B Wall; Hitoshi Suzuki; Archer D Smith; Stacy Hall; Knud Poulsen; Mogens Kilian; James A Mobley; Bruce A Julian; Jiri Mestecky; Jan Novak; Matthew B Renfrow
Journal:  Mol Cell Proteomics       Date:  2010-09-07       Impact factor: 5.911

7.  Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: implications for IgA nephropathy.

Authors:  Matthew B Renfrow; C Logan Mackay; Michael J Chalmers; Bruce A Julian; Jiri Mestecky; Mogens Kilian; Knud Poulsen; Mark R Emmett; Alan G Marshall; Jan Novak
Journal:  Anal Bioanal Chem       Date:  2007-08-22       Impact factor: 4.142

8.  Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.

Authors:  Milan Raska; Kazuo Takahashi; Lydie Czernekova; Katerina Zachova; Stacy Hall; Zina Moldoveanu; Matt C Elliott; Landon Wilson; Rhubell Brown; Dagmar Jancova; Stephen Barnes; Jana Vrbkova; Milan Tomana; Phillip D Smith; Jiri Mestecky; Matthew B Renfrow; Jan Novak
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

9.  IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1.

Authors:  Hitoshi Suzuki; Zina Moldoveanu; Stacy Hall; Rhubell Brown; Huong L Vu; Lea Novak; Bruce A Julian; Milan Tomana; Robert J Wyatt; Jeffrey C Edberg; Graciela S Alarcón; Robert P Kimberly; Yasuhiko Tomino; Jiri Mestecky; Jan Novak
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

10.  Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels.

Authors:  Z Moldoveanu; R J Wyatt; J Y Lee; M Tomana; B A Julian; J Mestecky; W-Q Huang; S R Anreddy; S Hall; M C Hastings; K K Lau; W J Cook; J Novak
Journal:  Kidney Int       Date:  2007-03-07       Impact factor: 10.612

View more
  4 in total

1.  N-acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy.

Authors:  Milada Stuchlova Horynova; Alena Vrablikova; Tyler J Stewart; Kazuo Takahashi; Lydie Czernekova; Koshi Yamada; Hitoshi Suzuki; Bruce A Julian; Matthew B Renfrow; Jan Novak; Milan Raska
Journal:  Nephrol Dial Transplant       Date:  2014-10-03       Impact factor: 5.992

2.  Quantitative assessment of successive carbohydrate additions to the clustered O-glycosylation sites of IgA1 by glycosyltransferases.

Authors:  Tyler J Stewart; Kazuo Takahashi; Nuo Xu; Amol Prakash; Rhubell Brown; Milan Raska; Matthew B Renfrow; Jan Novak
Journal:  Glycobiology       Date:  2021-06-03       Impact factor: 4.313

3.  Expression of the functional recombinant human glycosyltransferase GalNAcT2 in Escherichia coli.

Authors:  Jennifer Lauber; René Handrick; Sebastian Leptihn; Peter Dürre; Sabine Gaisser
Journal:  Microb Cell Fact       Date:  2015-01-13       Impact factor: 5.328

4.  Enzymatic sialylation of IgA1 O-glycans: implications for studies of IgA nephropathy.

Authors:  Kazuo Takahashi; Milan Raska; Milada Stuchlova Horynova; Stacy D Hall; Knud Poulsen; Mogens Kilian; Yoshiyuki Hiki; Yukio Yuzawa; Zina Moldoveanu; Bruce A Julian; Matthew B Renfrow; Jan Novak
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.